{"id":"W3189971813","doi":"10.1016/j.ejca.2021.05.040","title":"Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Chugai Pharmaceutical; Genentech; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Cancer Research UK; Seagen; Cilag; Puma Biotechnology; Arog Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Symphogen; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Amgen; Deciphera Pharmaceuticals; Takeda Oncology; Halozyme; Sanofi; GlaxoSmithKline; Celgene; Daiichi Sankyo Europe; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Clinical endpoint; Oncology; Internal medicine; Confidence interval; Clinical trial; Surrogate endpoint","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003859516,0.0001540761,0.0007510419,0.0001157129,0.00005624579,0.00003499778,0.00008895859,0.00005192171,0.00034099],"category_scores_gemma":[0.002758068,0.0001155409,0.0005450834,0.0002426695,0.00004346671,0.00007781513,0.00002258105,0.0003420887,0.000006845323],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002399065,"about_ca_system_score_gemma":0.001517194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006005892,"about_ca_topic_score_gemma":0.00002648972,"domain_scores_codex":[0.9964481,0.001022861,0.001785482,0.0002323385,0.0002728286,0.0002383638],"domain_scores_gemma":[0.9973264,0.0004219126,0.000918711,0.000143873,0.0009429084,0.0002462441],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03205168,0.002636202,0.0003810879,0.00002968313,0.0005836455,0.0002614302,0.0002465865,0.000003486909,0.180202,0.000001494144,0.01380305,0.7697996],"study_design_scores_gemma":[0.06840702,0.05188371,0.002162542,0.0004004954,0.0008105639,0.0002963608,0.0001381462,0.0001617992,0.01716246,0.000004640307,0.8583926,0.0001796344],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860858,0.002976145,0.002113922,0.005100155,0.002521457,0.0008277459,0.0001517008,0.00001587912,0.0002071355],"genre_scores_gemma":[0.9810453,0.001237721,0.0056906,0.005740191,0.005231731,0.00003153494,0.00002001239,0.00006768255,0.0009351934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8445896,"threshold_uncertainty_score":0.4711621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1061919721028062,"score_gpt":0.4763975619444084,"score_spread":0.3702055898416022,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}